Skip to main content
Top
Published in: Cancer Causes & Control 5/2019

01-05-2019 | Lung Cancer | Original paper

Second primary lung cancer in United States Cancer Survivors, 1992–2008

Authors: Nicholas M. Donin, Lorna Kwan, Andrew T. Lenis, Alexandra Drakaki, Karim Chamie

Published in: Cancer Causes & Control | Issue 5/2019

Login to get access

Abstract

Purpose

Lung cancer is common and lethal, and can occur in survivors of previous cancers. We sought to describe the incidence and mortality attributable to second primary lung cancers (SPLC) among survivors of other cancers, and to identify survivors at highest risk.

Methods

We identified adults diagnosed with a localized malignancy from non-pulmonary cancer sites from surveillance, epidemiology, and end results (SEER) data from 1992 to 2008. We explored factors associated with the incidence and death from SPLC using bivariable and multivariable models. Finally, we compared standardized incidence rates for SPLC in our cohort with the control arm of the National Lung Screening Trial (NLST), a randomized lung cancer screening trial.

Results

We identified 1,450,837 survivors of non-pulmonary cancers, of whom 25,472 developed SPLC at a mean (SD) follow-up of 5.7 (3.6) years. Over half (57%) of patients with SPLC died of the disease. Survivors of cancer of the hypopharynx, oropharynx, tonsil, and larynx, experienced SPLC at standardized incidence rates which greatly exceeded that observed in the control arm of the NLST (572/100,000 person-years). Additionally, survivors of bladder and esophageal cancer had rates that approached the NLST control arm rate. Increasing age and being divorced/widowed/separated were independent risk factors for SPLC in most primary cancer types.

Conclusion

The incidence of SPLC in survivors of certain primary cancers greatly exceeds the rate observed in the control arm of the NLST. Further study could help determine if screening for lung cancer in these cancer survivors could prevent death from lung cancer.
Appendix
Available only for authorised users
Literature
2.
go back to reference Miller KD et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefPubMed Miller KD et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefPubMed
3.
go back to reference Curtis RE et al (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda, (NIH Publ. No. 05-5302) Curtis RE et al (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda, (NIH Publ. No. 05-5302)
4.
go back to reference Donin N et al (2016) Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122:3075–3086CrossRefPubMed Donin N et al (2016) Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122:3075–3086CrossRefPubMed
6.
go back to reference Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Accessed 3 Mar 2017 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2013/​, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Accessed 3 Mar 2017
7.
go back to reference Team TNLSTR (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409CrossRef Team TNLSTR (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409CrossRef
8.
go back to reference National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health (2014) The health consequences of smoking—50 Years of progress: a report of the surgeon general. (Centers for Disease Control and Prevention (US)) National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health (2014) The health consequences of smoking—50 Years of progress: a report of the surgeon general. (Centers for Disease Control and Prevention (US))
9.
go back to reference Percy C, Van Holten V, Muir C (1990) International classification of diseases for oncology, 2nd edition. World Health Organization, Washington, D.C. Percy C, Van Holten V, Muir C (1990) International classification of diseases for oncology, 2nd edition. World Health Organization, Washington, D.C.
10.
12.
go back to reference Cohen EEW et al (2016) American cancer society head and neck cancer survivorship care guideline. CA Cancer J Clin 66:203–239CrossRefPubMed Cohen EEW et al (2016) American cancer society head and neck cancer survivorship care guideline. CA Cancer J Clin 66:203–239CrossRefPubMed
13.
go back to reference Wood DE (2015) National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin 25:185–197CrossRefPubMed Wood DE (2015) National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin 25:185–197CrossRefPubMed
14.
go back to reference Tammemägi MC et al (2014) Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 11:e1001764CrossRefPubMedPubMedCentral Tammemägi MC et al (2014) Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 11:e1001764CrossRefPubMedPubMedCentral
18.
go back to reference Corrao MA, Guindon GE, Cokkinides V, Sharma N (2000) Building the evidence base for global tobacco control. Bull World Health Organ 78:884–890PubMedPubMedCentral Corrao MA, Guindon GE, Cokkinides V, Sharma N (2000) Building the evidence base for global tobacco control. Bull World Health Organ 78:884–890PubMedPubMedCentral
20.
go back to reference Kuo JC-L, Raley RK (2016) Diverging patterns of union transition among cohabitors by race-ethnicity and education: trends and marital intentions. Demography 53:921–935CrossRefPubMed Kuo JC-L, Raley RK (2016) Diverging patterns of union transition among cohabitors by race-ethnicity and education: trends and marital intentions. Demography 53:921–935CrossRefPubMed
21.
go back to reference Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEcon 21:1315–1330CrossRef Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEcon 21:1315–1330CrossRef
22.
go back to reference Rink M et al (2013) Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63:724–732CrossRefPubMed Rink M et al (2013) Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63:724–732CrossRefPubMed
23.
go back to reference Do K-A et al (2004) Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 101:2837–2842CrossRefPubMed Do K-A et al (2004) Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 101:2837–2842CrossRefPubMed
24.
go back to reference Bjurlin MA et al (2013) Brief smoking cessation intervention: a prospective trial in the urology setting. J Urol 189:1843–1849CrossRefPubMed Bjurlin MA et al (2013) Brief smoking cessation intervention: a prospective trial in the urology setting. J Urol 189:1843–1849CrossRefPubMed
Metadata
Title
Second primary lung cancer in United States Cancer Survivors, 1992–2008
Authors
Nicholas M. Donin
Lorna Kwan
Andrew T. Lenis
Alexandra Drakaki
Karim Chamie
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 5/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01161-7

Other articles of this Issue 5/2019

Cancer Causes & Control 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine